基于首次人体血浆和尿液数据的阿普霉素群体药代动力学以支持有效剂量预测
阿普霉素正作为EBL-1003开发用于人类,以应对耐多药细菌。本研究基于30名健康志愿者的I期升剂量试验数据建立群体药代动力学模型,预测有效剂量为30 mg/kg每日一次静脉输注30分钟。
要点
- 阿普霉素清除率与绝对eGFR成正比,所有固定效应参数按总体重异速缩放。
- 典型个体(eGFR 124 mL/min,体重70 kg)清除率5.5 L/h,稳态分布容积16 L。
- 预测有效剂量30 mg/kg每日一次在模拟II期患者中达标概率96.4%。
核心结论
- 结果支持阿普霉素以预测有效剂量30 mg/kg每日一次进一步开展II期临床试验。
研究设计与样本
- 首次人体I期试验,静脉输注30分钟,五个升剂量组(0.3至30 mg/kg),从30名健康志愿者采集血浆和尿液样本。
- 采用逐步法建立群体药代动力学模型,最终模型用于PTA分析。
主要发现
- 四房室群体药代动力学模型、线性消除和肾脏分数排泄90%可描述数据。
- 阿普霉素清除率与绝对eGFR成正比,所有固定效应参数按总体重异速缩放。
- 典型个体(绝对eGFR 124 mL/min,总体重70 kg)清除率估计为5.5 L/h,稳态分布容积为16 L。
- PTA分析显示,预测有效剂量(30 mg/kg每日一次,30分钟静脉输注)在绝对eGFR外推至80 mL/min的虚拟II期患者人群中,当MIC为8 mg/L时,达到游离AUC/MIC目标40的概率为96.4%。
关键数值与推荐
- 预测有效剂量:30 mg/kg每日一次,30分钟静脉输注。
- 在MIC 8 mg/L时,游离AUC/MIC目标40的达标概率为96.4%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Apramycin is under development for human use as EBL-1003, a crystalline free base of apramycin, in face of increasing incidence of multidrug-resistant bacteria. Both toxicity and cross-resistance, commonly seen for other aminoglycosides, appear relatively low owing to its distinct chemical structure. OBJECTIVES: To perform a population pharmacokinetic (PPK) analysis and predict an efficacious dose based on data from a first-in-human Phase I trial. METHODS: The drug was administered intravenously over 30 min in five ascending-dose groups ranging from 0.3 to 30 mg/kg. Plasma and urine samples were collected from 30 healthy volunteers. PPK model development was performed stepwise and the final model was used for PTA analysis. RESULTS: A mammillary four-compartment PPK model, with linear elimination and a renal fractional excretion of 90%, described the data. Apramycin clearance was proportional to the absolute estimated glomerular filtration rate (eGFR). All fixed effect parameters were allometrically scaled to total body weight (TBW). Clearance and steady-state volume of distribution were estimated to 5.5 L/h and 16 L, respectively, for a typical individual with absolute eGFR of 124 mL/min and TBW of 70 kg. PTA analyses demonstrated that the anticipated efficacious dose (30 mg/kg daily, 30 min intravenous infusion) reaches a probability of 96.4% for a free AUC/MIC target of 40, given an MIC of 8 mg/L, in a virtual Phase II patient population with an absolute eGFR extrapolated to 80 mL/min. CONCLUSIONS: The results support further Phase II clinical trials with apramycin at an anticipated efficacious dose of 30 mg/kg once daily.
引用
- Zhao C, Chirkova A, Rosenborg S, et al. Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose. J Antimicrob Chemother. 2022. PMID: 35849148. doi:10.1093/jac/dkac225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。